Domains of Estrogen Receptor
(ER
) Required for ER
/Sp1-Mediated Activation of GC-Rich Promoters by Estrogens and Antiestrogens in Breast Cancer Cells
Kyounghyun Kim,
Nguyen Thu,
Brad Saville and
Stephen Safe
Department of Veterinary Physiology & Pharmacology (K.K., N.T., S.S.) and Department of Biochemistry & Biophysics (B.S.), Texas A&M University, College Station, Texas 77843-4466
Address all correspondence and requests for reprints to: Stephen H. Safe, Department of Veterinary Physiology & Pharmacology, Texas A&M University, 4466 TAMU, College Station, Texas 77843-4466. E-mail: ssafe{at}cvm.tamu.edu.
 |
ABSTRACT
|
---|
Estrogen receptor
(ER
)/Sp1 activation of GC-rich gene promoters in breast cancer cells is dependent, in part, on activation function 1 (AF1) of ER
, and this study investigates contributions of the DNA binding domain (C) and AF2 (DEF) regions of ER
on activation of ER
/Sp1. 17ß-Estradiol (E2) and the antiestrogens 4-hydroxytamoxifen and ICI 182,780 induced reporter gene activity in MCF-7 and MDA-MB-231 cells cotransfected with human or mouse ER
(hER
or MOR), but not ERß and GC-rich constructs containing three tandem Sp1 binding sites (pSp13) or other E2-responsive GC-rich promoters. Estrogen and antiestrogen activation of hER
/Sp1 was dependent on overlapping and different regions of the C, D, E, and F domains of ER
. Antiestrogen-induced activation of hER
/Sp1 was lost using hER
mutants deleted in zinc finger 1 [amino acids (aa) 185205], zinc finger 2 (aa 218245), and the hinge/helix 1 (aa 265330) domains. In contrast with antiestrogens, E2-dependent activation of hER
/Sp1 required the C-terminal F domain (aa 579595), which contains a ß-strand structural motif. Moreover, in peptide competition experiments overexpression of a C-terminal (aa 575595) F domain peptide specifically blocked E2-dependent activation of hER
/Sp1, suggesting that F domain interactions with nuclear cofactors are required for ER
/Sp1 action.
 |
INTRODUCTION
|
---|
THE NUCLEAR RECEPTOR superfamily of transcription factors includes the ligand-activated steroid and thyroid hormone, vitamin D and retinoid receptors, and several orphan receptors with unknown endogenous ligands (1, 2, 3, 4, 5, 6). Transcriptional activation induced by steroid hormone receptors requires initial ligand binding and formation of a nuclear hormone receptor dimer that interacts with cognate hormone response elements in promoter regions of responsive genes. DNA-bound nuclear hormone receptors activate the basal transcription machinery through interactions with a growing number of coregulatory proteins including coactivators, p300, cAMP response element binding protein-associated factor, and TATA binding protein-associated factors (7, 8, 9, 10, 11, 12, 13). Functional and physical interactions of these factors with several steroid hormonereceptors have been reported; however, the precise assembly of interacting proteins has not been defined and depends on the specific receptor, cell, and promoter context (14, 15).
Ligand-activated estrogen receptor
(ER
) and ERß signaling pathways have been extensively investigated and involve interactions of ER homo- or heterodimers with estrogen responsive elements (EREs) in 17ß-estradiol (E2) responsive gene promoters (1, 2, 3, 4, 5, 6, 15, 16, 17, 18, 19). Several studies have also described ligand-activated ER action through activator protein 1 (AP1) elements in which transcriptional enhancement is associated with interactions between ER and the c-jun component of the AP1 complex (20, 21, 22, 23, 24, 25). Estrogens and antiestrogens activate ER
/AP1; however, this response is ligand structure and cell context dependent, as antiestrogens exhibit minimal agonist activity in breast cancer cells. In contrast, ERß/AP1 is preferentially activated by antiestrogens but not E2 or diethylstilbestrol (20). Research in this laboratory has identified GC-rich motifs in promoters of several E2-responsive genes that are activated by ER
/Sp1 and, like ER/AP1, this hormone-dependent response does not require direct binding of ER to promoter elements and is activated by HE11, a DNA-binding domain (DBD) deletion mutant of ER
(26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36). Human ER
(hER
)/Sp1 is activated by estrogens and antiestrogens in MCF-7 and MDA-MB-231 breast cancer and LnCaP prostate cancer cells but not in HeLa cells. In contrast, hERß/Sp1 exhibits minimal activity in all cell lines examined (35). Studies with wild-type hER
, various hERß chimeras, and mutants demonstrated that the activation function 1 (AF1) region of hER
was required for hER
/Sp1-mediated transactivation in MCF-7 and MDA-MB-231 breast cancer cells; however, this did not exclude a role for AF2 in this response (35).
This study further investigates estrogen and antiestrogen activation of hER
/Sp1 action in MCF-7 and MDA-MB-231 breast cancer cells and AF1-independent domains of ER
required for ligand-dependent transactivation. Estrogen activation of hER
/Sp1 is observed in cells transfected with wild-type hER
and deletions of one or both zinc fingers and point mutations in helix 12 (D538N, E542Q, and D545N) that block interactions with AF2-interacting coactivators. Activation of hER
/Sp1 by E2 is not observed in hER
mutants with deletion of the hinge region [amino acids (aa) 271300] or helix 12 and the F domain (aa 538595), whereas these latter mutants are activated by the antiestrogens 4-hydroxytamoxifen (4-OHT) and ICI 182,780. In contrast, antiestrogen activation of hER
/Sp1 is not observed with zinc finger 1 or zinc finger 2 deletion mutants. Thus, hER
/Sp1 activation by estrogens and antiestrogens is complex and requires multiple domains of hER
.
 |
RESULTS
|
---|
Role of Zinc Fingers 1 and 2 of ER
and ERß in Hormonal Activation of GC-Rich Promoters
Previous studies in this laboratory showed that hormone-induced activation of hER
/Sp1 in breast cancer cells required the AF1 domain of hER
(35), and activation by E2 was also observed in cells cotransfected with the DBD deletion mutant (aa 185251) hER11 (26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36). The role of other domains of hER
on estrogen and antiestrogen activation of hER
/Sp1 has not been defined and is investigated in this study. Although hER
11/Sp1 is activated by E2, deletion of the entire DBD resulted in loss of antiestrogen-induced transactivation (35, 37), and therefore initial studies determined the role of zinc fingers 1 and 2 deletion mutants on estrogen/antiestrogen activation of ER
/Sp1.
Wild-type and zinc finger deletion mutants for hER (
and ß) and mouse ER
(MOR) (Table 1
) were cloned into pcDNA3 and translated in vitro using [35S]methionine, and the radiolabeled proteins were separated by SDS-PAGE (Fig. 1A
). The results show that in vitro translated proteins gave distinct bands with comparable intensities and the expected molecular weights, indicating that the
ZF1 or
ZF2 deletions did not cause unexpected frame shifts. The effects of
ZF1 and
ZF2 mutations on DNA binding were determined by gel EMSAs of the in vitro expressed proteins. The results showed that only wild-type hERs and MOR formed retarded bands after incubation with [32P]ERE (lanes 3, 7, and 10), whereas DNA-bound complexes were not observed with the zinc finger deletion mutants (Fig. 1B
). Transcriptional activation assays in ER-negative MDA-MB-231 cells cotransfected with an ERE-dependent promoter (pERE3) and wild-type ER or ER deletion mutants showed that E2 induced activity only in cells transfected with wild-type hER (
or ß) or MOR (Fig. 1C
). These results were consistent with the gel mobility shift assays showing that the zinc finger mutants do not bind EREs (Fig. 1B
).

View larger version (31K):
[in this window]
[in a new window]
|
Figure 1. Characterization of Wild-Type and DBD ER Mutants
A, SDS-PAGE separation of in vitro translated 35S-labeled proteins. Wild-type hER , MOR, and hERß and their corresponding zinc finger deletion mutants were in vitro translated using [35S]methionine and separated by SDS-PAGE as described in Materials and Methods. 11C refers to a DBD deletion mutant (aa 185281) of hER . Intensities of the radiolabeled proteins were similar and electrophoretic mobilities were consistent with their expected molecular masses. B, Gel mobility shift assays. Unlabeled wild-type hER , MOR, and hERß and their corresponding zinc finger deletion mutants were in vitro translated, incubated with [32P]ERE, and analyzed by gel mobility shift assays as described in Materials and Methods. UPL refers to unprogrammed lysate. Only wild-type hER (lane 3), hERß (lane 7), and MOR (lane 10) formed retarded bands. Competition with excess unlabeled ERE decreased intensities of these bands (data not shown). C, Transactivation in MDA-MB-231 cells transfected with pERE3. MDA-MB-231 cells were treated with 10 nM E2, cotransfected with pERE3 and wild-type hER , MOR, and hERß or their zinc finger deletion mutants, and luciferase activities were determined as described in Materials and Methods. Significant (P < 0.05) induction is indicated (*). Results are expressed as means ± SD for at least three separate determinations for each treatment group.
|
|
E2 induced reporter gene activity in MDA-MB-231 and MCF-7 cells transfected with pSp13 and expression plasmids for wild-type hER
or MOR (Fig. 2
). In contrast to results obtained in cells transfected with pERE3, induction responses were observed for both zinc finger deletion mutants of hER
and MOR. hERß and the DBD deletion mutants were only minimally active in MDA-MB-231 cells (
2-fold induction) and inactive in MCF-7 cells (data not shown). The fold-induction using wild-type and zinc finger deletion mutants of hER
and MOR was lower in MDA-MB-231 than MCF-7 breast cancer cells due, in part, to higher basal activity in the former cell line. The highest induction responses using pSp13 and E2 were observed in MCF-7 cells transfected with
ZF2 mutants; in MCF-7 cells, all the ER-DBD deletion mutants were more potent activators of pSp13 than wild-type hER
or MOR. The overall pattern of induction responses was similar for wild-type hER
and MOR and their zinc finger deletion mutants, and subsequent studies used only hER
.

View larger version (19K):
[in this window]
[in a new window]
|
Figure 2. Activation of pSp13 by Wild-Type and Zinc Finger Deletion Mutants of ER
MDA-MB-231 (A) and MCF-7 cells (B). Cells were treated with 10 nM E2, transfected with pSp13 and wild-type hER or MOR and their zinc finger deletion mutants, and luciferase activities were determined as described in Materials and Methods. Significant (P < 0.05) induction is indicated (*). Only minimal responses were observed for hERß/Sp1 (data not shown) as previously reported (35 ), and similar results were obtained with the hERß zinc finger deletion mutants. Results are expressed as means ± SD for three separate determinations for each treatment group.
|
|
Several genes that are induced by E2 in MCF-7 breast cancer cells through hER
/Sp1 interactions with GC-rich motifs have previously been identified (26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36), and these include retinoic acid receptor
1 and adenosine deaminase (29, 30). hER
/Sp1 activation of constructs derived from GC-rich E2-responsive regions of the adenosine deaminase (pADA; -86 to -65) and retinoic receptor
1 (pRAR
1; -79 to -49) gene promoters were investigated in MCF-7 and MDA-MB-231 cells transfected with wild-type or zinc finger deletion mutants of hER
(Fig. 3
). The pattern of induction by E2 was dependent on expression of wild-type or variant hER
, promoter, and cell context. For example, hormone inducibility was higher in MDA-MB-231 cells transfected with either pADA or pRAR
1 and wild-type hER
compared with responses observed for the zinc finger deletion mutants. In MCF-7 cells, hormone inducibility was highest in cells transfected with pADA or pRAR
1 and the
ZF2 deletion mutant of hER
.
Role of Zinc Fingers 1 and 2 in Antiestrogen Activation of GC-Rich pSp13
Results in Fig. 4A
summarize the effects of E2 and the antiestrogens ICI 182,780 and 4-OHT on induction of luciferase activity in MCF-7 cells transfected with pSp13 and wild-type or zinc finger deletion mutants of hER
. Both estrogens and antiestrogens induce transactivation in cells transfected with wild-type hER
, whereas E2, but not the antiestrogens, were active in cells transfected with
ZF1 or
ZF2 deletion mutants of hER
. These results suggest that antiestrogen-bound zinc finger mutants of hER
are transcriptionally inactive and their recruitment of functional coactivators requires cooperative interactions that are directly or indirectly dependent on the zinc finger domains of hER
. Although deletion of one or both zinc fingers resulted in loss of antiestrogen-dependent hER
/Sp1 agonist activity, 4-OHT and ICI 182,780 inhibited E2-induced ER
/Sp1 action using these DBD deletion constructs, suggesting that the antiestrogen-mediated responses are intact in cells expressing zinc finger mutants of hER
. We also investigated the possibility that the failure to observe antiestrogen activation of zinc finger mutants of hER
/Sp1 may be due to failure of the transfected constructs to accumulate in nuclei of breast cancer cells. However, results of immunofluorescent studies in MDA-MB-231 cells transfected with hER
or the zinc finger mutants showed that wild-type and mutant constructs were primarily nuclear in cells treated with dimethylsulfoxide (DMSO) or E2/antiestrogens, although some perinuclear staining was observed with hER
ZF1 using ICI 182,780 (Fig. 4B
).

View larger version (42K):
[in this window]
[in a new window]
|
Figure 4. Effects of Zinc Finger DBD AF2 Mutants of hER on Activation of pSp13 by Estrogens and Antiestrogens in MCF-7 Cells
A, Effect of hER and zinc finger mutants. Cells were treated with 10 nM E2, 1 µM 4-OHT, 1 µM ICI 182,780 (ICI), or antiestrogens plus E2, transfected with pSp13 and hER , hER ZF1, and hER ZF2, and luciferase activities were determined as described in Materials and Methods. Significant (P < 0.05) induction (*) and inhibition of E2-induced activity (**) are indicated. B, Immunostaining of transfected wild-type and mutant hER constructs in MDA-MB-231 cells. Cells were transfected with hER , hER ZF1, or hER ZF2, treated with 10 nM E2, 1 µM 4-OHT, or 1 µM ICI 182,780 for 24 h, and immunostaining of transfected ER constructs was determined as described in Materials and Methods. Nuclear staining was observed in all groups; however, there were some ICI 182,780-treated cells that exhibited some perinuclear staining.
|
|
Activation of hER
/Sp1 by E2, 4-OHT, and ICI 182,780 Does Not Require AF2-Helix 12-Coactivator Interactions
Saville et al. (35) previously reported that activation of hER
/Sp1 by E2 was lost after deletion of aa 51117; however, this did not exclude a role for AF2 alone or as a modifier of AF1-dependent hER
/Sp1 action. hER
TAF1 contains three aa mutations (D538N, E542Q, and D545N) that do not affect ligand binding but inactivate AF2 by selectively blocking interactions with AF2-dependent coactivators (38, 39, 40, 41). In MCF-7 cells transfected with pSp13 and hER
TAF1, E2 significantly induced reporter gene activity, and ICI 182,780 and 4-OHT also slightly increased this response (Fig. 5A
). Hormone-mediated transactivation was also observed in MCF-7 cells transfected with pSp13 and hER
TAF1 containing deletions of zinc finger 1 or zinc finger 2 in the DBD; in contrast, the antiestrogens ICI 182,780 and 4-OHT did not activate luciferase activity using the hER
TAF1 DBD mutants, and similar results were observed for hER
ZF1 and hER
ZF2 (Fig. 4A
). Increased hormone-induced transactivation was observed in MCF-7 cells transfected with pSp13 and hER
ZF1 or hER
ZF2 compared with wild-type hER
(Figs. 2B
and 4A
). In contrast, deletion of zinc fingers 1 or 2 in hER
TAF1 did not result in increased hormone responsiveness in MCF-7 cells transfected with the zinc finger deletion mutants compared with hER
TAF1 (Fig. 5A
). This suggests that helix 12 may contribute to E2-induced hER
ZF1/Sp1 and hER
ZF2/Sp1 action. hER
19 and hER
null were also inactive, and this was consistent with previous studies showing the importance of AF1 for hER
/Sp1 action (35). The results in Fig. 5B
show that expression of the LXXLL peptide 2XF6 (38) significantly decreased hormone-induced transactivation in MDA-MB-231 cells transfected with pERE3, and inhibition was not observed in cells transfected with pSp13.

View larger version (36K):
[in this window]
[in a new window]
|
Figure 5. AF2-Independent Activation of hER /Sp1 by Estrogens and Antiestrogens
A, Activation of hER /Sp1 by helix 12 and zinc finger mutants of hER . MCF-7 cells were treated with DMSO, 10 nM E2, 1 µM 4-OHT, or 1 µM ICI 182,780, transfected with several hER point and/or deletion mutants, and luciferase activity was determined as described in Materials and Methods. The hER 19C and hER null mutants do not express AF1 (aa 1178) of hER , and hER null also contains D538N, E542Q, and D545N point mutations in the AF2 domain of hER . Results are expressed as means ± SD for three separate determinations for each treatment group and significant (P < 0.05) induction is indicated (*). B, Inhibition of transactivation by 2XF6 peptide. MDA-MB-231 cells were treated with DMSO or 10 nM E2, transfected with pERE3 or pSp13 and different amounts of 2XF6 expression plasmid, and luciferase activity was determined as described in Materials and Methods. Results are expressed as means ± SD for three replicate determinations for each treatment group, and significant (P < 0.05) inhibition of induced activity is indicated (**). MCF-7 (C) or MDA-MB-231 (D) cells were transfected with pSp13, hER , and different amounts of coactivators SRC-1, SRC-2, SCR-3, and p68 RNA helicase (10, 50, or 100 ng), treated with E2, and luciferase activities were determined as described in Materials and Methods. Significant (P < 0.05) coactivation (*) or inhibition (* ) of E2-induced activities are indicated; similar results were observed after transfecting higher amounts (500 ng) of each coactivator in both cell lines. Results are expressed as means ± SD for three separate experiments for each treatment group. E, Coactivation of hER action in CHO cells transfected with pERE3. Cells were transfected with pERE3 and treated as described above. Significant (P < 0.05) coactivation of E2-induced activity is indicated (*). Results are expressed as means ± SD for three separate experiments for each treatment group.
|
|
These data suggest that interactions of hER
with prototypical steroid receptor coactivators containing LXXLL motifs may not be critical for hER
/Sp1 action. Coactivators of hER
and other nuclear receptors have been extensively investigated, and these include AF2-dependent steroid receptor coactivators (SRCs) and AF1-dependent p68 RNA helicase (42, 43). However, many of these coactivators have not been investigated in breast cancer cells, and their coactivation of hER
/Sp1 through LXXLL-dependent or -independent pathways has not been reported previously. Figure 5
, CE, summarizes the effects of selected coactivators on hER
/Sp1 in breast cancer cells transfected with pSp13 and on hER
/pERE3 in Chinese hamster ovary (CHO) cells, which have commonly been used for coactivation studies. MCF-7 cells were treated with 10 nM E2, transfected with pSp13 and hER
, and different amounts (10, 50, and 100 ng) of expression plasmids for SRC-1, SRC-2 (glucocorticoid receptor interacting protein 1), SRC-3 (AIB1), and p68 RNA helicase, an AF1-dependent coactivator of ER
(on an ERE promoter; Ref. 43). E2 induced activity (
2-fold; Fig. 5C
); however, cotransfection with SRC-1, SRC-2, SRC-3, or p68 did not enhance activity in this cell line, and similar results were observed for the RNA coactivator SRA or p300 and for higher amounts (500 ng) of transfected coactivators (data not shown). A parallel experiment was carried out in MDA-MB-231 cells (Fig. 5D
), and E2 induced activity (
2-fold), but cotransfection with SRC-1, SRC-2, SRC-3, and p68 did not enhance hER
/Sp1 action. Moreover, many of these coactivators significantly inhibited the induction response in breast cancer cells. As a positive control for coactivation, we also investigated effects of p160 coactivators and p68 in CHO cells treated with 10 nM E2 and transfected with pERE3 and hER
. This cell line has frequently been used to demonstrate coactivation of hER
using ERE-dependent promoter-reporter constructs. E2 induced luciferase activity (8- to 15-fold) and SRC-1, SRC-2, and SRC-3 (but not p68) enhanced the induction response (Fig. 5E
). Coactivation of hER
/Sp1 by SRCs was not observed in ER-positive or negative breast cancer cell lines; this was consistent with the importance of AF1 for hER
/Sp1-mediated transactivation (35). Surprisingly, we did not observe coactivation of hER
or hER
/Sp1 by the AF1-interacting coactivator p68 in ER-negative or -positive cell lines, suggesting that cell context modulates the effects of p68 as a coactivator.
Role of AF2/Hinge (DEF) Region for Activation of hER
/Sp1 by Estrogen and Antiestrogens
We further investigated requirements for other regions within the DEF domains for activation of hER
/Sp1 by estrogens and antiestrogens in MCF-7 cells. E2, 4-OHT, and ICI 182,780 did not induce luciferase activity in MCF-7 cells transfected with pSp13, whereas a 2.5- to 4.5-fold induction was observed by all three compounds in cells cotransfected with hER
(Fig. 6A
). E2 did not induce activity in MCF-7 cells transfected with hER
(
271300) or hER
(
265330) which contain deletions of the hinge (D) or hinge (D) plus helix 1 of the E domain. ICI 182,780 and 4-OHT were also inactive in cells transfected with hER
(
265330), whereas induction by the antiestrogens was observed in cells transfected with hER
(
271300). Estrogen/antiestrogen-dependent activation of hER
/Sp1 was also investigated in MCF-7 cells transfected with a series of C-terminal deletion mutants, namely hER
(
538595), hER
(
554595), and hER
(
579595). These mutants contain deletions of helix 12 (E) and the C-terminal F domain (538595), the F domain (554595) alone, and the ß-strand region of the F domain (579595). In MCF-7 cells, both 4-OHT and ICI 182,780 induced luciferase activity in cells transfected with these hER
deletion mutants, whereas E2 was inactive. The failure of E2 to induce transactivation in cells transfected with pSp13 and hER
(
579595) suggests that the C-terminal aa 579595, which contains a QKYYIT ß-strand motif (44), may be critical for transcriptional activation by E2 but not 4-OHT or ICI 182,780. We further confirmed the F domain requirement for hormonal activation of hER
/Sp1 by examining a similar series of hER
deletion mutants in MDA-MB-231 cells cotransfected with pSp13 or pERE3. E2 induced transactivation in cells cotransfected with pERE3 and hER
(
271300) or hER
(
554595), confirming results of previous studies in other cell lines showing that the hinge region and F domain are not necessary for hormonal activation of ER
/pERE (42, 44, 45, 46, 47, 48). E2 did not induce transactivation in MCF-7 or MDA-MB-231 cells cotransfected with pSp13 and hER
(
554595). Thus, hormonal activation of hER
/Sp1 by E2 was dependent on the hinge (D) and F domains of hER
, whereas these same regions of hER
were not required for activation of pERE3.

View larger version (32K):
[in this window]
[in a new window]
|
Figure 6. Effects of DEF Domain Mutants of hER on Hormone and Antiestrogen-Induced Transactivation
A, Transfection of pSp13 in MCF-7 cells. Cells were transfected with pSp13 and wild-type or variant hER , and induction of luciferase activity by 10 nM E2, 1 µM 4-OHT, or 1 µM ICI 182,780 was determined as described in Materials and Methods. Significant (P < 0.05) induction is indicated by an asterisk. B, Hormonal activation of pERE3 or pSp13 in MDA-MB-231 cells. Cells were treated with DMSO or 10 nM E2, transfected with wild-type or variant hER and pERE3 or pSp13, and luciferase activity was determined as described in Materials and Methods. Significant (P < 0.05) induction is indicated by an asterisk. C, Inhibition of transactivation by Fß peptide. MDA-MB-231 cells were transfected with pERE3 or pSp13, treated with DMSO or 10 nM E2, and cotransfected with Fß (F domain) peptide, and luciferase activity was determined as described in Materials and Methods. Significant (P < 0.05) decreases in hormone-induced activity by Fß peptide is indicated (**).
|
|
Peptides targeted to different regions of hER
block hormone-induced transactivation of ERE-dependent promoters/genes (38, 39, 48). This has been extensively investigated with peptides containing LXXLL motifs that block coactivator interactions with ER
(38, 39) and inhibit hormone-induced activation in cells transfected with pERE3 (Fig. 5B
). Hormone-induced transactivation in MDA-MB-231 cells transfected with pERE3 was not significantly decreased after cotransfection with the F-ß strand peptide containing aa 575595 from the F domain of hER
fused to the DBD of the yeast GAL4 protein. In contrast, the F domain peptide blocked hormone-induced transactivation in MDA-MB-231 cells transfected with pSp13, whereas the 2XF6 peptide was inactive, and similar results were obtained with other peptides containing LXXLL sequences (data not shown). These results are consistent with the activity of wild-type and variant hER
constructs and confirm that the F domain of ER
is also essential for E2-dependent activation of hER
/Sp1.
 |
DISCUSSION
|
---|
Development of selective ER modulators (SERMs) for treatment of breast cancer and other hormone-related problems is dependent on their tissue-specific activation or inhibition of ER-mediated genes/responses (49, 50, 51, 52, 53). There are an increasing number of factors that regulate cell context-dependent ER action, and these include relative expression of ER subtypes and a complex network of nuclear proteins that uniquely interact with specific surfaces or domains of ER
, ERß, and other coregulatory proteins (7, 8, 9, 10, 11, 12, 13). The classical mechanism of ER activation involves ligand-dependent formation of ER dimers that bind consensus or nonconsensus EREs and recruit SRCs and other nuclear proteins that facilitate interactions with basal transcription factors (1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13). In contrast, nonclassical pathways that involve ligand activation of ER/Sp1 and ER/AP1 do not require interactions of ER with promoter DNA but with other DNA-bound transcription factors, namely Sp1 and c-jun, respectively. Research in this laboratory has identified a number of E2-responsive genes regulated by ER
/Sp1 (26) in breast cancer cells (27, 28, 29, 30, 31, 32, 33, 34, 35, 36), suggesting that the nonclassical pathways for activation of ER
may play a significant role in cell context-dependent regulation of genes by E2 and SERMs.
Previous studies showed that both estrogens and antiestrogens activated a construct containing a GC-rich promoter (pSp1) in breast cancer cells and this response was AF1 dependent (35). Moreover, the DBD of hER
was not required for activation by E2, whereas deletion of this region resulted in loss of transactivation by 4-OHT/ICI 182,780 (35, 54). We have further investigated the effects of selective mutations (deletions) of zinc fingers 1 and 2 on estrogen and antiestrogen activation of hER
/Sp1 in breast cells. As expected, the zinc finger deletion mutants of hER
, hERß, and MOR did not bind [32P]ERE in gel mobility shift assays or activate an ERE promoter (Fig. 1A
). However, E2 activated pSp13, pADA, and pRAR in MCF-7 and MDA-MB-231 cells transfected with wild-type hER
(and MOR) and both zinc finger mutants (Figs. 2
and 3
), and similar results were obtained in MCF-7 cells transfected with wild-type and zinc finger mutants of hER
TAF1 (Fig. 5A
). In contrast, minimal responses were observed for hERß/Sp1 (data not shown) as previously reported (35). Zinc fingers 1 and 2 are important for DNA binding, and the D box region of zinc finger 2 plays a role in ER
homodimerization (42, 55). The DBD of ER
is also an important determinant for antiestrogen activation of ER
/AP1 and ER
/Sp1. Point mutations in zinc finger 1 either decreased (E207G/G208S), eliminated (K201A), or did not affect (E207A/G208A) ICI 182,780 activation of ER
/AP1 in TSA cells, whereas an A227T mutation in zinc finger 2 resulted in loss of ICI 182,780 inducibility through an AP1 element (25). E2 decreased activation of ER
/AP1 in MCF-7 and TSA cells, and this was also observed in all but one (K210a) of the DBD point mutants (25). We also investigated activation of hER
/Sp1 by the zinc finger point mutants (25) in breast cancer cells, and minimal transactivation was observed after treatment with E2, 4-OHT, or ICI 182,780 (data not shown). In contrast, deletion of the DBD of hER
did not affect activation of hER
/Sp1 by E2 in breast cancer cells (35); however, our results show that both zinc fingers of hER
and hER
TAF1 are required for the activity of antiestrogens (Fig. 5
). Thus, there are significant differences between hER
/Sp1 and ER
/AP1 and their requirements for regions within the DBD for activation by E2 and SERMs, suggesting that cell context-specific interactions of nuclear proteins with the DBD region of hER
may be important for ligand-dependent activation of hER
/Sp1. DBD-interacting proteins that coactivate hER
and other hormone receptors have been reported (56, 57, 58), and current studies are investigating coactivation of hER
/Sp1 by SNURF, a small RING finger protein initially identified as an androgen receptor DBD-interacting protein.
Previous studies with AF1 deletion mutants of hER
showed that aa 51117 were required for ER
/Sp1-mediated responses (35); however, contributions of the DEF domains have not been determined. The AF2 domain of hER
and other nuclear receptors is required for ligand-dependent activation of hER
through classical DNA-dependent pathways, and this activation process involves recruitment of AF2-interacting coactivators (7, 8, 9, 10, 11, 12, 13). NR box (LXXLL) motifs in SRCs and other coactivators specifically interact with helix 12 of hER
. D538N, E542Q, and D545N mutations in helix 12 give hER
TAF1 abrogate interactions with most AF2-interacting coactivators and decrease transactivation from ERE promoters (38, 39, 40, 41). Maximal ER
/AP1 activation by E2 requires intact activation surfaces of both AF1 and AF2, and AF2-dependent responses require helix 12 and the corresponding NR box interacting sites. Moreover, the AF1 domain of ER
inhibits antiestrogen-induced ER
/AP1 action (21). In contrast, both estrogens and antiestrogens activated hER
and hER
TAF1/Sp1, and overexpression of the NR box peptide 2XF6 (38) derived from SRC-2 did not affect activation of hER
/Sp1 but inhibited ER
on an ERE promoter (Fig. 5B
). These results imply that regions of AF2 that interact with coactivators through their NR boxes are not necessary for hER
/Sp1 action, and this is supported by studies showing that prototypical AF2-interacting SRCs did not enhance hER
/Sp1-mediated transactivation in breast cancer cells transfected with pSp13 (Fig. 5
). Interestingly, p68, an AF1-interacting protein, also did not enhance hER
/Sp1 activation of a GC-rich promoter in breast cancer cells, indicating that AF1-dependent p68 coactivation of hER
previously observed in COS-1 and HeLa cells transfected with an ERE promoter is also dependent on cell context (43). Results obtained with hER
TAF1, the SRCs, and peptide competition experiments clearly define that some mechanistic differences between hormone-dependent activation of hER
/Sp1 and hER
are due, in part, to helix 12 of hER
.
We further investigated other regions within the DEF domains required for ligand-dependent activation of hER
/Sp1 (Fig. 6
). The antiestrogens 4-OHT and ICI 182,780 activated hER
/Sp1 in MCF-7 cells transfected with hER
(
271300), a hinge region deletion mutant (Fig. 6A
), whereas E2 was inactive. In contrast, E2 activated an ERE promoter in MDA-MB-231 cells transfected with hER
(
271300) (Fig. 6B
), and this was consistent with previous reports showing that the hinge region was not required for activation of ERE-dependent constructs (42). Deletion of the hinge region and helix 1 [i.e. hER
(
265330)] resulted in loss of E2 and antiestrogen activation of hER
and hER
/Sp1 (Fig. 6
, A and B), and the importance of helix 1 within the E domain for activation of ERE-dependent promoters has previously been reported (42). Pissios and co-workers (59) recently showed that E2, 4-OHT, and ICI 182,780 induced interactions of a helix 1-GAL4 chimeric protein with the ligand binding domain (LBD) or ER
in a mammalian two-hybrid assay. Thus, helix 1 may stabilize ligand interactions with the LBD, and this process may be functional for both DNA-dependent and -independent mechanisms of ER
action. However, the importance of helices 1 and 2 as interacting domains for other nuclear factors has not been determined.
Activation of hER
/Sp1 by estrogens was also dependent on the C-terminal region of hER
(aa 538595), which encompassed part of helix 12 within the E domain (aa 538553) and the F domain (aa 554595), which potentially contains helix 13 and ß-strand motifs based on secondary structure calculations (42, 58). Helix 12 is required for E2-dependent activation of ER
in cells transfected with an ERE promoter (42) (Fig. 6B
), and similar results were observed for activation of hER
/Sp1 by E2 (Fig. 6A
). In contrast, both 4-OHT and ICI 182,780 activated hER
(
538595)/Sp1, and this result coupled with antiestrogen activation of hER
TAF1/Sp1 confirms that helix 12 is not required for this induction response by antiestrogens. The failure of E2 to activate hER
(
538595)/Sp1 was not due to the requirement for helix 12 because activation was also not observed in cells transfected with hER
(
554595) (i.e. F domain deletion) or hER
(
579595) in which only the C-terminal ß-strand region of the F domain has been deleted. F domain deletions can modulate activation of ERE promoters by antiestrogens but have minimal effects on E2-mediated transactivation (45). However, the results in Fig. 6A
clearly demonstrate that F domain aa 579595 are required for activation of hER
/Sp1 by E2. This was also confirmed in selective NR box (2XF6) and F domain (aa 575595) peptide competition studies, which demonstrate preferential inhibition of hER
/Sp1 action in cells transfected with the Fß expression plasmid (Fig. 6C
). These results demonstrate that E2- and SERM-mediated activation of hER
/Sp1 in breast cancer cells is complex and dependent on multiple overlapping and distinct regions of hER
(Fig. 7
). These domains of hER
may impart unique structural features required for hER
/Sp1 action and may also serve as binding sites for essential interacting nuclear coregulatory proteins. Decreased hER
/Sp1-mediated transactivation in cells transfected with the F domain peptide (Fig. 6B
) suggests that this region of hER
may interact with other nuclear coregulatory proteins, and current studies are focused on identifying F domain-interacting factors and their function in breast cancer cells.
 |
MATERIALS AND METHODS
|
---|
Chemicals and Biochemicals
DMEM nutrient mixture F-12 (DME/F12) without phenol red, PBS, E2, 4-OHT, BSA (Fraction V), and 100x antibiotic/antimycotic solution were purchased from Sigma (St Louis, MO). Fetal bovine serum (FBS) was obtained from JRH Biosciences (Lenexa, KS). ICI 182,780 was kindly provided by Dr. Alan Wakeling (Astra USA, Inc.-Zeneca Pharmaceuticals, Macclesfield, UK). [
-32P]ATP (3000 Ci/mmol) was purchased from NEN Life Science Products (Boston, MA). Polydeoxy-(inosinic-cytidylic)acid, and T4-polynucleotide kinase were purchased from Roche Molecular Biochemicals (Indianapolis, IN). All the restriction enzymes and modifying enzymes (T4 DNA ligase, calf intestinal alkaline phosphatase) used in this study were purchased from Promega Corp. (Madison, WI) or Roche Molecular Biochemicals. Plasmid preparation kits were purchased from QIAGEN (Valencia, CA), and 40% polyacrylamide was obtained from National Diagnostics (Atlanta, GA). All other chemicals were obtained from commercial sources at the highest quality available.
Cell Maintenance and Transient Transfection Assay
MCF-7, CHO, and MDA-MB-231 cells were obtained from the American Type Culture Collection (ATCC, Manassas, VA). MCF-7, MDA-MB-231, and CHO cells were grown in DME/F12 (Sigma) supplemented with 2.2 g/liter sodium bicarbonate, 5% FBS, BSA (Sigma), and 10 ml/liter antibiotic/antimycotic solution (Sigma). Cells were cultured and maintained in 150-cm2 tissue culture dishes in a 37 C in 5% CO2-95% air. For transient transfection assays, cells were seeded onto six-well tissue culture plates in DME/F12 without phenol red supplemented with 2.2 g/liter sodium bicarbonate, 5% dextran-coated charcoal-stripped FBS, BSA, and 10 ml/liter antibiotic/antimycotic solution (Sigma). After 24 h, cells were transfected with the calcium phosphate method with 2 µg of luciferase reporter construct (pSp13, pERE3, pADA, and pRAR
1), 250 ng pcDNA3/His/lacZ (Invitrogen, Carlsbad, CA) as a standard reference for transfection efficiency, and 1 µg or 100 ng (for cotransfection with pERE3) of the appropriate ER expression plasmid. In studies where variable amounts of coactivators were also used, the amount of DNA transfected was kept at a constant value by adding sufficient amount of empty vector. After 56 h, the media were removed and cells were shocked with 20% glycerol in PBS (pH 7.4) for 1 min. Cells were rinsed twice with 1 ml of PBS and treated with 5% charcoal-stripped DME/F12 either containing DMSO, E2 (10 nM), 4-OHT (1 µM), or ICI 182,780 (1 µM) for 3640 h. After harvesting cells by scraping in 1x reporter lysis buffer (Promega Corp.), luciferase activity of aliquots of this extract were determined using the luciferase assay system (Promega Corp.). ß-Galactosidase activity was performed using Tropix Galacto-Light Plus assay system (Tropix, Bedford, MA). Light emission was detected on a lumicount micro-well plate reader (Packard Instruments, Meriden, CT), and luciferase reporter gene activity was corrected by normalizing against ß-galactosidase activity obtained from the same sample. Results are expressed as means ± SD with at least three determinations for each treatment group.
Oligonucleotides and Plasmids
hER
expression plasmid was kindly provided by Dr. Ming-jer Tsai (Baylor College of Medicine, Houston, TX); ER-null and hER
TAF1 and 2XF6 NR box peptide (fused to the yeast GAL4 DBD) were obtained from Dr. D. McDonnell (Duke University, Durham, NC). The hER deletion constructs hER11C, hER
(
265330) (HE15), and hER
(
271300) (HE12) were originally obtained from Dr. Pierre Chambon (Institut de Genetique et de Biologie Moleculaire et Cellulaire, Illkirch, France). MORs were generously provided by Dr. Malcom G. Parker (Imperial Cancer Research Fund, London, UK), and hERß was supplied by Dr. J. A. Gustafsson (Karolinska Institute, Huddinge, Sweden). Our experiments were carried out using a shorter variant form of ERß; however, in preliminary experiments using a longer form of ERß (provided by Dr. S. Mosselman, N.V. Organon, Oss, The Netherlands), minimal induction of ERß/Sp1 was also observed. SRC-1, SRC-2 (glucocorticoid receptor interacting protein 1), SRC-3 (AIB1), and p68 RNA helicase were graciously provided by Drs. B. OMalley (Baylor College of Medicine), M. R. Stallcup (University of Southern California, Los Angeles, CA), P. Meltzer (National Cancer Institute, Bethesda, MD), and S. Kato (University of Tokyo, Tokyo, Japan), respectively. The hER cDNAs and the MOR cDNA were inserted into vectors pcDNA3 or pcDNA3.1/His C (Invitrogen, Carlsbad, CA) in this laboratory for in vitro translation and for expression in mammalian cells in transient transfection assays. For gel mobility shift assays, a consensus estrogen response element (ERE); 5'-GTC CAA AGT CAG GTC ACA GTG ACC TGA TCA AAG TT-3' (sense) was used and obtained from the Gene Technologies Laboratories, Texas A&M University (College Station, TX). The DNA oligonucleotides used for construction of plasmids were also synthesized by the Gene Technologies Laboratories (Texas A&M University). pXP1 luciferase reporter construct was obtained from ATCC, and the minimal TATA sequences were inserted into pXP1 in this laboratory. The following promoter sequences were cloned into HindIII and BamHI sites of pXP1 TATA-luciferase reporter construct: three consensus GC-rich Sp1 binding sites for pSp13 (5'-GCT TAT TCG ATC G)GG GCG GGG CGA GCA TTC GAT CGG GGC GGG GCG AGC ATT GAT CGG GGC GGG GGC GAG CG-3' (sense)]; and three consensus EREs for pERE3 (5'-AGC TTT CCG GAT CTA)GGT CAC TGT GAC CCG GGA TCC TAG GTC ACT GTG ACC CGG GAT CCT AGG TCA CTG TGA CCT GAT CAA AGT G-3' (sense)]. The GC-rich genomic promoter sequence from RAR
1 gene (pRAR
1; -79 to -49) (5'-AGC TTG ATT GGT CGG T)GG GCG GGC AGG GGC GGG CCT-3' (sense)] and the GC-rich genomic promoter sequence from the pADA gene (-86 to -65) (5'-AGC TTG GCG AGA G)GG CGG GCC CCG GGA-3' (sense)] were also cloned into HindIII and BamHI sites of pXP1 luciferase reporter construct. The GC-rich and ERE motifs are underlined.
Generation of ER Deletion Mutant Constructs
ER DBD deletion constructs were prepared by site-directed mutagenesis by overlap extension using the PCR as previously described (60). For example, hER
ZF1 in pcDNA3 was constructed by carrying out the following procedures. One set of primers (A1/B1) from the HindIII site (A1) in the multiple cloning site in pcDNA3 to the site before the first amino acid in the region to be deleted was amplified by PCR; the latter primer (B1) has an overlapping region of approximately 15 to 20 bp that starts at the next amino acid in the deletion construct. In addition, another set of primers beginning just after the last amino acid to be deleted to the HindIII site in hER
cDNA sequence were also used and amplified by PCR. This second set of primers (A2/B2) contained a 15- to 20-bp overlapping region complementary to the last 15- to 20-bp DNA sequence in the first PCR product. Both PCR reaction products have their own regions of overlap, and these were coincubated to anneal the overlapping regions; this was followed by PCR amplification with the primer (A1) that starts at the multiple cloning site and the primer (B2) that starts at the hER
cDNA sequence. The resulting PCR product containing the desired deletion and a unique restriction site at both ends (HindIII) was purified, digested with HindIII, and finally cloned into pcDNA3 construct to give the appropriate expression plasmid for electrophoretic mobility shift and transient transfection assays.
The primers used for the mutagenesis assays are summarized in Table 1
. hER
ZF2 in pcDNA3 was also generated by using a unique HindIII restriction site for cloning into this vector. Generation of hERß
ZF1 and hERß
ZF2 used the unique NheI and EcoRI sites of previously modified hERß in pcDNA3.1 (35). MOR cDNA was inserted into EcoRI site of pMT2 mammalian expression vector that contains unique NotI and XbaI sites in MOR cDNA sequence suitable for cloning the PCR-amplified insert containing deletion of one zinc finger domain, into pMT2. The EcoRI fragment containing the desired deletion from pMT2 MOR vector was cloned into EcoRI site of pcDNA3.1 for in vitro translation. The hER
TAF1 construct (in pcDNA3) has three point mutations (D538N, E542Q, and D545N) in AF2 (40, 41). hER
TAF1
ZF1 and hER
TAF1
ZF2 constructs were created by cloning the XbaI fragment (
0.7 kb) from hER
TAF1 (in pcDNA3) into pcDNA3.1, and zinc finger mutants were prepared as described above. hER
(
538595) was made by PCR amplification of wild-type hER
using primer sets: (F1) 5'-TGC TAG CAT GAC CAT GAC CCT CCA CAC C-3' and (R1) 5'-GAC TCG AGT CAA GTG GGC GCA TGT AGG CGG TG-3'. hER
(
554595) and hER
(
579595) were also amplified with the same F1 primer above and (R2) 5'-GAC TCG AGT CAA GTG GGC GCA TGT AGG CGG TG-3' or (R3) 5'-TAC TCG AGT CAC AAG GAA TGC GAT GAA GTA GAG-3', respectively. The amplified fragments were digested and inserted into NheI and XhoI sites of pcDNA3.0 or 3.1 expression vector. GAL4-DBD fusion Fß peptide [21 amino acids from C-terminal end of hER
(aa 575595)] was made by using BamHI and HindIII sites within the multiple cloning region of pM vector (CLONTECH Laboratories, Inc., Palo Alto, CA) with (F) 5'-GAT CCG TTCA TCG CAT TCC TTG CAA AAG TAT TAC ATC ACG GGG GAG GCA GAG GGT TTC CCT GCC ACA GTC TGA A-3' and (R) 5'-AGC TTT CAG ACT GTG GCA GGA AAC CCT CTG CCT CCC CCG TGA TGT AAT ACT TTT GCA AGG AAT GCG ATG AAC G-3'. All constructs were mapped by restriction enzymes and sequenced to confirm that proper deletion or insertions were introduced into the target cDNA.
In Vitro Translation and Detection of the Translated Proteins
Wild-type ER and ER deletion mutants were synthesized in vitro using TNT T7 quick coupled transcription/translation System (Promega Corp.) in the presence or absence of [35S]methionine for EMSAs and separation by 10% SDS-PAGE.
EMSAs
The consensus [32P]ERE oligonucleotide was annealed and end labeled using T4-polynucleotide kinase and [
-32P]ATP. To characterize DNA binding of wild-type ER and corresponding zinc finger deletion mutants, 0.5 µl of in vitro translated protein or 0.5 µl of unprogrammed lysate was incubated in 1x binding buffer (25% glycerol, 0.5 mM EDTA, 0.5 mM dithiothreitol, 50 mM potassium chloride, 10 mM HEPES at pH 8.0) for 5 min at 4 C. Radiolabeled consensus ERE oligonucleotide (60,000 cpm) was added to the reaction, and the reaction mixture was incubated at 25 C for 15 min. Samples were then applied to the gel and separated by polyacrylamide gel electrophoresis at 120 V in 0.9 mM Tris, 0.9 M borate, 2 mM EDTA (pH 8.0) for 23 h. Protein-DNA complexes were visualized by autoradiography using X-Omat film (Eastman Kodak Co., Rochester, NY).
Fluorescence Immunocytochemistry
MDA-MB-231 cells were subcultured in four-well Lab-Tek chambered slides (Nunc Inc., Naperville, IL) in DME/F12 medium without phenol red 5% FBS stripped with dextran-coated charcoal. After 24 h, cells were transiently transfected with 500 ng of hER
or hER
mutant expression plasmids. For transient transfection studies, cells were incubated with FuGENE Transfection Reagent (Roche) at 37 C for 5 h, followed by 24 h of recovery in DME/F12. Before fixation, slides were washed three times in Dulbeccos PBS (DPBS) and then fixed for 10 min at -20 C at 100% methanol. For nuclear localization of ER, the rat monoclonal antibody raised against the N-terminal domain of the hER
(H184; Santa Cruz Biotechnology, Inc., Santa Cruz, CA) was diluted to a final concentration of 3 µg/ml in DPBS containing 0.5% BSA, 0.1% goat serum, and 0.3% Tween 20. Rat IgG at the same concentration was used as a control. Tween 20 (0.3%) was included in all antibody, blocking steps, and washes for nuclear localization of ER. Followed by incubation with H184 antibody for 16 h, cells were washed with DPBS (three times), then incubated for 1 h in a 1:200 dilution of fluorescein isothiocyanate-conjugated goat-antirat IgG (629511; Zymed Laboratories, Inc., South San Francisco, CA) in DPBS containing 0.1% goat serum. Cells were then washed (four times) over a period of 2 h and transferred to DPBS before coverslip mounting with ProLong Antifade mounting reagent (Molecular Probes, Inc., Eugene, OR). For each treatment, representative fluorescence images were recorded using an Axioplan microscope (Carl Zeiss, Thornwood, NY) equipped with a Hamamatsu chilled three charge-coupled device color camera (Hamamatsu, Japan) using Adobe Photoshop 5.0 (Adobe Systems, Seattle, WA) image capture software. Images from all treatment groups were captured at the same time using identical image capture parameters. Slides were subsequently washed three times in DPBS followed by a 1-h blocking step in 3% normal goat serum (G-9023; Sigma).
Statistics
For transient transfection studies, results are expressed as means ± SD for at least three separate experiments for each treatment group. Statistical differences (P < 0.05) between control (DMSO) and treatment groups or between E2-induced responses and treatment groups (coactivator experiments) were determined by ANOVA and Scheffes post hoc test.
 |
FOOTNOTES
|
---|
This work was supported in part by NIH Grant ES-09106 and the Texas Agricultural Experiment Station. S.S. is a Sid Kyle Professor of Toxicology.
Abbreviations: aa, Amino acids; ADA, adenosine deaminase; AF, activation function; AP1, activator protein 1; CHO, Chinese hamster ovary; DBD, DNA-binding domain; DMSO, dimethylsulfoxide; DPBS, Dulbeccos PBS; E2, 17ß-estradiol; ER, estrogen receptor; ERE, estrogen responsive element; FBS, fetal bovine serum; hER, human ER; MOR, mouse ER
; 4-OHT, 4-hydroxytamoxifen; RAR, retinoic acid receptor; SERM, selective ER modulator; SRC, steroid receptor coactivator.
Received for publication December 5, 2002.
Accepted for publication January 27, 2003.
 |
REFERENCES
|
---|
- Tsai MJ, OMalley BW 1994 Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem 63:451486[CrossRef][Medline]
- Beato M, Herrlich P, Schutz G 1995 Steroid hormone receptors: many actors in search of a plot. Cell 83:851857[Medline]
- Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P, Evans RM 1995 The nuclear receptor superfamily: the second decade. Cell 83:835839[Medline]
- Enmark E, Gustafsson JA 1996 Orphan nuclear receptorsthe first eight years. Mol Endocrinol 10:12931307[Medline]
- Perlmann T, Evans RM 1997 Nuclear receptors in Sicily: all in the famiglia. Cancer Res Cell 90:391397
- Kliewer SA, Lehmann JM, Willson TM 1999 Orphan nuclear receptors: shifting endocrinology into reverse. Science 284:757760[Abstract/Free Full Text]
- Horwitz KB, Jackson TA, Bain DL, Richer JK, Takimoto GS, Tung L 1996 Nuclear receptor coactivators corepressors. Mol Endocrinol 10:11671177[Abstract]
- Glass CK, Rose DW, Rosenfeld MG 1997 Nuclear receptor coactivators. Curr Opin Cell Biol 9:222232[CrossRef][Medline]
- Edwards DP 1999 Coregulatory proteins in nuclear hormone receptor action. Vitam Horm 55:165218[Medline]
- McKenna NJ, Xu J, Nawaz Z, Tsai SY, Tsai MJ, OMalley BW 1999 Nuclear receptor coactivators: multiple enzymes, multiple complexes, multiple functions. J Steroid Biochem Mol Biol 69:312[CrossRef][Medline]
- Robyr D, Wolffe AP, Wahli W 2000 Nuclear hormone receptor coregulators in action: diversity for shared tasks. Mol Endocrinol 14:329347[Free Full Text]
- Lemon BD, Freedman LP 1999 Nuclear receptor cofactors as chromatin remodelers. Curr Opin Genet Dev 9:499504[CrossRef][Medline]
- Klinge CM 2000 Estrogen receptor interactions with co-activators and corepressors. Steroids 65:227251[CrossRef][Medline]
- Chen JD 2000 Steroid/nuclear receptor coactivators. Vitam Horm 58:391448[Medline]
- Katzenellenbogen JA, Katzenellenbogen BS 1996 Nuclear hormone receptors: ligand-activated regulators of transcription and diverse cell responses. Chem Biol 3:529536[Medline]
- Cowley SM, Hoare S, Mosselman S, Parker MG 1997 Estrogen receptors
and ß form heterodimers on DNA. J Biol Chem 272:1985819862[Abstract/Free Full Text]
- Barkhem T, Carlsson B, Nilsson Y, Enmark E, Gustafsson J, Nilsson S 1998 Differential response of estrogen receptor
and estrogen receptor ß to partial estrogen agonists/antagonists. Mol Pharmacol 54:105112[Abstract/Free Full Text]
- Hyder SM, Chiappetta C, Stancel GM 1999 Interaction of human estrogen receptors
and ß with the same naturally occurring estrogen response elements. Biochem Pharmacol 57:597601[CrossRef][Medline]
- Hall JM, McDonnell DP 1999 The estrogen receptor ß-isoform (ERß) of the human estrogen receptor modulates ER
transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology 140:55665578[Abstract/Free Full Text]
- Paech K, Webb P, Kuiper GG, Nilsson S, Gustafsson J, Kushner PJ, Scanlan TS 1997 Differential ligand activation of estrogen receptors ER
and ERß at AP1 sites. Science 277:15081510[Abstract/Free Full Text]
- Webb P, Nguyen P, Valentine C, Lopez GN, Kwok GR, McInerney E, Katzenellenbogen BS, Enmark E, Gustafsson J-Å, Nilsson S, Kushner PJ 1999 The estrogen receptor enhances AP-1 activity by two distinct mechanisms with different requirements for receptor transactivation functions. Mol Endocrinol 13:16721685[Abstract/Free Full Text]
- Webb P, Lopez GN, Uht RM, Kushner PJ 1995 Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens. Mol Endocrinol 9:443456[Abstract]
- Uht RM, Anderson CM, Webb P, Kushner PJ 1997 Transcriptional activities of estrogen and glucocorticoid receptors are functionally integrated at the AP-1 response element. Endocrinology 138:29002908[Abstract/Free Full Text]
- Weatherman RV, Scanlan TS 2001 Unique protein determinants of the subtype-selective ligand responses of the estrogen receptors (ER
and ERß) at AP-2 sites. J Biol Chem 276:38273832[Abstract/Free Full Text]
- Jakacka M, Ito M, Weiss J, Chien P-Y, Gehm BD, Jameson JL 2001 Estrogen receptor binding to DNA is not required for its activity through the nonclassical AP1 pathway. J Biol Chem 276:1361513621[Abstract/Free Full Text]
- Porter W, Saville B, Hoivik D, Safe S 1997 Functional synergy between the transcription factor Sp1 and the estrogen receptor. Mol Endocrinol 11:15691580[Abstract/Free Full Text]
- Wang F, Hoivik D, Pollenz R, Safe S 1998 Functional and physical interactions between the estrogen receptor-Sp1 and the nuclear aryl hydrocarbon receptor complexes. Nucleic Acids Res 26:30443052[Abstract/Free Full Text]
- Wang W, Dong L, Saville B, Safe S 1999 Transcriptional activation of E2F1 gene expression by 17ß-estradiol in MCF-7 cells is regulated by NF-Y-Sp1/estrogen receptor interactions. Mol Endocrinol 13:13731387[Abstract/Free Full Text]
- Xie W, Duan R, Safe S 1999 Estrogen induces adenosine deaminase gene expression in MCF-7 human breast cancer cells: role of estrogen receptor-Sp1 interactions. Endocrinology 140:219227[Abstract/Free Full Text]
- Sun G, Porter W, Safe S 1998 Estrogen-induced retinoic acid receptor
1 gene expression: role of estrogen receptor-Sp1 complex. Mol Endocrinol 12:882890[Abstract/Free Full Text]
- Qin C, Singh P, Safe S 1999 Transcriptional activation of insulin-like growth factor binding protein 4 by 17ß-estradiol in MCF-7 cells: role of estrogen receptor-Sp1 complexes. Endocrinology 140:25012508[Abstract/Free Full Text]
- Duan R, Porter W, Safe S 1998 Estrogen-induced c-fos protooncogene expression in MCF-7 human breast cancer cells: role of estrogen receptor Sp1 complex formation. Endocrinology 139:19811990[Abstract/Free Full Text]
- Dong L, Wang W, Wang F, Stoner M, Reed JC, Harigai M, Kladde M, Vyhlidal C, Safe S 1999 Mechanisms of transcriptional activation of bcl-2 gene expression by 17ß-estradiol in breast cancer cells. J Biol Chem 174:3209932107[CrossRef]
- Samudio I, Vyhlidal C, Wang F, Stoner M, Chen I, Kladde M, Barhoumi R, Burghardt R, Safe S 2001 Transcriptional activation of DNA polymerase
gene expression in MCF-7 cells by 17ß-estradiol. Endocrinology 142:10001008[Abstract/Free Full Text]
- Saville B, Wormke M, Wang F, Nguyen T, Enmark E, Kuiper G, Gustafsson J-A, Safe S 2000 Ligand-, cell- and estrogen receptor subtype (
/ß)-dependent activation at GC-rich (Sp1) promoter elements. J Biol Chem 275:53795387[Abstract/Free Full Text]
- Xie W, Duan R, Chen I, Samudio I, Safe S 2000 Transcriptional activation of thymidylate synthase by 17ß-estradiol in MCF-7 human breast cancer cells. Endocrinology 141:24392449[Abstract/Free Full Text]
- Duan R, Porter W, Samudio I, Vyhlidal C, Kladde M, Safe S 1999 Transcriptional activation of c-fos protooncogene by 17ß-estradiol: mechanism of aryl hydrocarbon receptor-mediated inhibition. Mol Endocrinol 13:15111521[Abstract/Free Full Text]
- Chang C, Norris JD, Gron H, Paige LA, Hamilton PT, Kenan DJ, Fowlkes D, McDonnell DP 1999 Dissection of the LXXLL nuclear receptor-coactivator interaction motif using combinatorial peptide libraries: discovery of peptide antagonists of estrogen receptors
and ß. Mol Cell Biol 19:82268239[Abstract/Free Full Text]
- Schaufele F, Chang CY, Liu WQ, Baxter JD, Nordeen SK, Wan YH, Day RN, McDonnell DP 2000 Temporally distinct and ligand-specific recruitment of nuclear receptor-interacting peptides and cofactors to subnuclear domains containing the estrogen receptor. Mol Endocrinol 14:20242039[Abstract/Free Full Text]
- Tzukerman MT, Esty A, Santiso-Mere D, Danielian P, Parker MG, Stein RG, Pike JW, McDonnell DP 1994 Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. Mol Endocrinol 8:2130[Abstract]
- McDonnell DP, Clemm DL, Hermann T, Goldman ME, Pike JW 1995 Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. Mol Endocrinol 9:659669[Abstract]
- Kumar V, Green S, Stack G, Berry M, Jin J-R, Chambon P 1987 Functional domains of the human estrogen receptor. Cell 51:941951[Medline]
- Endoh H, Maruyama K, Masuhiro Y, Kobayashi Y, Goto M, Tai H, Yanagisawa J, Metzger D, Hashimoto S, Kato S 1999 Purification and identification of p68 RNA helicase acting as a transcriptional coactivator specific for the activation function 1 of human estrogen receptor
. Mol Cell Biol 19:53635372[Abstract/Free Full Text]
- Schwartz JA, Zhong L, Deighton-Collins S, Zhao C, Skafar DF 2002 Mutations targeted to a predicted helix in the extreme carboxyl-terminal region of the human estrogen receptor-
alter its response to estradiol and 4-hydroxytamoxifen. J Biol Chem 277:1320213209[Abstract/Free Full Text]
- Montano MM, Müller V, Trobaugh A, Katzenellenbogen BS 1995 The carboxy-terminal F domain of the human estrogen receptor: role in the transcriptional activity of the receptor and the effectiveness of antiestrogens as estrogen antagonists. Mol Endocrinol 9:814825[Abstract]
- Nichols M, Rientjes JM, Stewart AF 1998 Different positioning of the ligand-binding domain helix 12 and the F domain of the estrogen receptor accounts for functional differences between agonists and antagonists. EMBO J 17:765773[Abstract/Free Full Text]
- Peters GA, Khan SA 1999 Estrogen receptor domains E and F: role in dimerization and interaction with coactivator RIP-140. Mol Endocrinol 13:286296[Abstract/Free Full Text]
- Koide A, Abbatiello S, Rothgery L, Koide S 2002 Probing protein conformational changes in living cells by using designer binding proteins: application to the estrogen receptor. Proc Natl Acad Sci USA 99:12531258[Abstract/Free Full Text]
- McDonnell DP 1999 The molecular pharmacology of SERMs. Trends Endocrinol Metab 10:301311[CrossRef][Medline]
- Smith CL, OMalley BW 1999 Evolving concepts of selective estrogen receptor action: from basic science to clinical applications. Trends Endocrinol Metab 10:299300[CrossRef][Medline]
- Jordan VC 1999 Targeted antiestrogens to prevent breast cancer. Trends Endocrinol Metab 10:312317[CrossRef][Medline]
- Fuqua SA, Russo J, Shackney SE, Stearns ME 2000 Estrogen, estrogen receptors and selective estrogen receptor modulators in human breast cancer. J Womens Cancer 2:2132
- Krishnan V, Heath H, Bryant HU 2001 Mechanism of action of estrogens and selective estrogen receptor modulators. Vitam Horm 60:123147
- Porter W, Wang F, Duan R, Qin C, Castro-Rivera E, Safe S 2001 Transcriptional activation of heat shock protein 27 gene expression by 17ß-estradiol and modulation by antiestrogens and aryl hydrocarbon receptor agonists: estrogenic activity of ICI 164,384. J Mol Endocrinol 26:3142[Abstract/Free Full Text]
- Schwabe JW, Neuhaus D, Rhodes D 1990 Solution structure of the DNA-binding domain of the oestrogen receptor. Nature 348:458461[CrossRef][Medline]
- Moilanen AM, Poukka H, Karvonen U, Hakli, Jänne OA, Palvimo JJ 1998 Identification of a novel RING finger protein as a coregulator in steroid receptor-mediated gene transcription. Mol Cell Biol 18:51285139[Abstract/Free Full Text]
- Saville B, Poukka H, Wormke M, Jänne OA, Palvimo JJ, Stoner M, Samudio I, Safe S 2002 Cooperative coactivation of estrogen receptor
in ZR-75 human breast cancer cells by SNURF and TATA-binding protein. J Biol Chem 277:24852497[Abstract/Free Full Text]
- Ko L, Cardona GRH, Chin WW 2002 Identification and characterization of a tissue-specific coactivator, GT198, that interacts with the DNA-binding domains of nuclear receptors. Mol Cell Biol 22:357369[Abstract/Free Full Text]
- Pissios P, Tzameli I, Kushner P, Moore DD 2000 Dynamic stabilization of nuclear receptor ligand binding domains by hormone or corepressor binding. Mol Cell 6:245253[Medline]
- Ho SN, Hunt HD, Horton RM, Pullen JK, Pease LR 1989 Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene 77:5159[CrossRef][Medline]